DuPont de Nemours, Inc. · NYSE:DD

DuPont de Nemours — DuPont — Credit Suisse Chemical and Ag Science Conference 2013

21 slides from DuPont de Nemours's conference presentation, Sep 19, 2013

  1. Slide 1: Credit Suisse Chemical and Ag Science Conference

    Credit Suisse Ellen Kullman Chemical and Ag Science Conference Chair of the Board & Chief Executive Officer September 19, 2013 New York City E. I. du Pont de Nemours & Company 1

  2. Slide 2: Regulation G and Forward Looking Statements

    Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this data is meaningful to investors because it provides insight with respect to ongoing operating results of the company and

  3. Slide 3: Clear Strategy, Stronger Company… Superior Return to Shareholders

    Clear Strategy, Stronger Company… … Superior Return to Shareholders 3

  4. Slide 4: Three Strategic Priorities To Increase The Value Of DuPont

    Three Strategic Priorities To Increase The Value Of DuPont… Ag & Nutrition Bio‐based Advanced 1. Extend our Industrials Materials leadership across the 2. Develop world‐ 3. Strengthen and high‐value, science‐ leading industrial grow our leading position driven segments of the biotechnology in differ

  5. Slide 5: In Conjunction With Three Operational Priorities

    …In Conjunction With Three Operational Priorities Innovation Global Reach Execution Increasing Return on R&D Driving Penetration In Fast‐ • Delivering Ongoing Growing, Developing Productivity Markets • Optimizing resource allocation • Returning cash to shareholders Our efforts to accelerate growth,

  6. Slide 6: Stronger Positions in Secular Growth Markets

    Stronger Positions in Secular Growth Markets Agriculture Food Biosciences Automotive Mobile Devices, Solar/Energy Protection Displays Well Positioned in Growth Markets 6

  7. Slide 7: Increased CapEx And R&D For Higher Growth Businesses

    Increased CapEx And R&D For Higher Growth Businesses $4.0 +33% 3% Total $3.5 13% Increase CapEx And R&D Spend Profile ($B)* $3.0 7% $2.5 20% $2.0 84% $1.5 $1.0 73% $0.5 $0.0 2007 2012 Core Segments (1) Performance Chemicals Performance Coatings Positioning DuPont For Greater Growth Through Increased

  8. Slide 8: Ongoing Portfolio Enhancement Through Major M&A

    Ongoing Portfolio Enhancement Through Major M&A… 2012 Segment Sales Performance Industrial Biosciences Coatings Safety & Protection Agriculture Performance $34.8B* Materials Electronics & Communications Performance Nutrition & Chemicals Health Positioning DuPont For Future Growth – Higher Growth And

  9. Slide 9: Aggressive Cost Cutting And Working Capital Improvements

    DuPont Has Implemented Aggressive Cost Cutting And Working Capital Improvements Cost Reductions Working Capital Savings Since 12/31/08: • Days Payable Outstanding (DPO) increased by 11% Announced Cost Reductions $2.0B • Days Sales Outstanding (DSO) decreased by 12% Cost Reductions Achieved >$2.2B •

  10. Slide 10: Significant Improvement in Segment Operating Margins

    Significant Improvement in Segment Operating Margins Operating Margin* 2008 – 2012 Segments 2008 2012 Improvement (BPS) Agriculture 15.4% 20.5% 507 Electronics & Communications 11.3% 9.6% (171) Industrial Biosciences ‐ 13.7% ‐ Nutrition & Health 2.5% 9.3% 683 Performance Chemicals 10.9% 25.2% 1,430

  11. Slide 11: Strong Performance Despite Pharma License Expiration

    Strong Performance Despite Pharma License Expiration $4.0 $3.6 $3.5 $0.1 $3.0 Net Income ($B) $2.5 $2.2 $2.0 $0.7 $3.5 $1.5 $1.0 $1.5 $0.5 $0.0 2008 1/1/2008 1/1/2009 1/1/2010 1/1/2011 2012 1/1/2012 (1) (2) Net Income (less Pharma) Pharma Net Income DuPont Has Greatly Exceeded Pharma’s Contribution

  12. Slide 12: TSR & Capital Returned Outperformed Peers And Market

    DuPont TSR & CAPITAL RETURNED Significantly Outperformed Peers And The Broader Market Total Capital Returned Total Shareholder Return to Shareholders (12/31/08 – 9/13/13)(1) (2009 – 2012)(4) DuPont 182% DuPont 4.9% (2) Proxy Peers 95% Proxy Peers 4.5% S&P S&P (3) 156% 3.7% Chemicals Chemicals S&P 50

  13. Slide 13: Building A Higher Growth, Higher Value Company

    Building A Higher Growth, Higher Value Company 13

  14. Slide 14: Broad Science And Innovation Capabilities Create Growth Opportunity

    DuPont’s Broad Science And Innovation Capabilities Create A Large And Accelerating Growth Opportunity World Class Integrated …Compelling Market Insights Science Coupled With… To Solve World Scale Challenges Food Integration of emerging biological Energy sciences Engineering Chemistry Protection Mate

  15. Slide 15: Portfolio Strength And Strategic Alignment

    Portfolio Strength And Strategic Alignment: DuPont Leverages Capabilities Across Its Technology Platform To Drive Innovation And Growth Product: Rynaxypyr® Product: Zytel® RS / Hytrel® RS Function: Breakthrough insect Function: Renewably sourced control, excellent environmental lightweight materials

  16. Slide 16: DuPont Has A Strong and Balanced Pipeline

    DuPont Has A Strong and Balanced Pipeline Discovery Development Launch Probiotics Biobutanol Cyazypyr® Seed Treatment Next Gen OLED Automotive Fluoropolymers TPC Bio-THF Opteon® Cold H2O YF Canola Enzymes Plenish® Zytel® Next Gen Bio-Isoprene PV: Nylons Cellulosic AcreMax® Food Front side Ethanol si

  17. Slide 17: Drive Greater Penetration Into Fast-Growing Developing Markets

    Drive Greater Penetration Into Fast‐Growing Developing Markets Rapidly Growing Developing Markets Sales Danisco Case Study 32% • Prior to its acquisition by DuPont, Danisco $12.0 $11.1 accessed developing markets via distributors with a negative impact on margins $9.0 25% • Today, Danisco leverages

  18. Slide 18: Dividends Will Continue To Be A Priority

    Dividends Will Continue To Be A Priority… Dividends per Share Stability and Growth Focus $1.78 • Continuous dividend since 1904 • No reduction in dividend during recession $1.70 or post Pharma license expiration • Dividend growth restarted $1.64 $1.64 $1.64 • Dividend yield and payout ratio are abov

  19. Slide 19: To Be Complemented With Share Buybacks

    …To Be Complemented With Share Buybacks Capital Returned To Shareholders Comments $10B $9B • Capital returned to shareholders has Cumulative Capital Returned $8B $7B accelerated: To Shareholders ($B) $6B $5B • Two recent dividend increases $4B $3B $2B $1B • $1B share repurchase with Performance Coat

  20. Slide 20: What You Can Expect

    What You Can Expect Strategic Priorities Operational Priorities Extend Ag & Nutrition Leadership Innovation Build Bio‐based Businesses Global Reach Strengthen Advanced Materials Execution 7% Sales CAGR 12% Operating EPS CAGR Long Term Growth Targets 20

  21. Slide 21: Copyright DuPont trademarks notice

    Copyright © 2013 DuPont. All rights reserved. The DuPont Oval Logo, DuPontTM The miracles of scienceTM, and all products denoted with ® or TM are trademarks or registered trademarks of E. I. du Pont de Nemours and Company. 21

DuPont — Credit Suisse Chemical and Ag Science Conference 2013 on 6ix